Newly created position is head of motion painting talent
Andrew Rogers has been tapped for a new created stance as head of the motion impression talent department at Paradigm.
A seven-year vet of the agency, Rogers already has helped cut the careers of a number of up-and-comers including Michael Cera ("Juno" and the upcoming "Youth in Revolt"), Mary Elizabeth Winstead ("Live Free and Die Hard" and the approaching "Make It Happen") and Moon Bloodgood ("Terminator 4"). He too has worked closely with "ER" regular Mekhi Phifer, who will be the lead in Broadway's "Guess Who's Coming to Dinner," and Laz Alonso, world Health Organization toplines Spike Lee's forthcoming "Miracle at St. Anna."
In his raw role, Rogers will be responsible for assigning and implementing coverage of flick projects from all the studios and key production companies vis-a-vis talent, making sure that the office is maximising client opportunities in that area, both in footing of acquiring jobs and making the best possible deals.
Rogers continues to be the point agent for his dozen or so clients and will oversee close to 25 agents on both coasts.
He told The Reporter that he -- under Paradigm's encouragement -- has been singularly focused on portion to identify younger gift, nurture their careers and hang on to them as clients. At the same fourth dimension, Rogers has made contributions to expanding opportunities for some of the agency's more established clientele, including getting Chris Cooper tortuous with the movie "Breach."
Paradigm chairperson Sam Gores said Rogers achieves perfect balance betwixt his roles as "an aggressive and relentless" agent and "a creative and thoughtful" guide in steering a client's career.
Rogers will liaise regularly with Steve Small and Michael Lazo, co-heads of the Paradigm talent department, but fundamentally will be empowered to run his department. The loose reporting dynamic is not dissimilar to how department heads interface with more senior agents or agency partners at other top shops around town.
Rogers begins his modern job immediately.
More info
Sunday 24 August 2008
Thursday 14 August 2008
GTCbio Announces Largest Annual Conference - The 4th Modern Drug Discovery & Development Summit - Oct 15-17, 2008, San Diego
�GTCbio just announced the scheduling of one of the largest industry conferences taking place on October 15-17, 2008 in San Diego, CA. The 4th Modern Drug Discovery & Development features six full conferences, trey symposia, sestet stand-alone roger Sessions, and a plenary tonic session presenting some of the leaders in the field.
Now in its fourth year, the summit meeting will in one case again provide a landscape and in-depth industry analysis streaming through different alterative and target areas, examining the current advancements and addressing the question that's on everyone's mind - where is the manufacture headed next?
The Summit's six private tracks will focus on biological therapeutics, translational practice of medicine, drug pattern & lead discovery, emergent targets & therapeutics, pharmacokinetics & pharmacodynamics, and partnering, licensing & outsourcing. The three symposia taking position the showtime morning of the height will feature article presentations on stem cells as tools for drug discovery, tomography technologies, and regulatory updates in the industry.
Leading presenters from all o'er the world will come to San Diego on the 15th, 16th and 17th to discuss the outlook of the biopharmaceutical market blank space. Presenting organizations include, Pfizer, Merck, Novartis, Eli Lilly, GSK, Aventis, Genentech, Amgen, Biogen Idec, NIH, FDA & many more.
For more info on attending, presenting a poster, or sponsoring, please visit hypertext transfer protocol://www.gtcbio.com.
About GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to help the substitution of biopharmaceutical and biomedical intelligence 'tween industry leadership, academic and government organizations, and the financial community.
GTCbio is a subsidiary company of Global Technology Community, LLC, a privately held company founded in 2002.
http://www.gtcbio.com
More information
Now in its fourth year, the summit meeting will in one case again provide a landscape and in-depth industry analysis streaming through different alterative and target areas, examining the current advancements and addressing the question that's on everyone's mind - where is the manufacture headed next?
The Summit's six private tracks will focus on biological therapeutics, translational practice of medicine, drug pattern & lead discovery, emergent targets & therapeutics, pharmacokinetics & pharmacodynamics, and partnering, licensing & outsourcing. The three symposia taking position the showtime morning of the height will feature article presentations on stem cells as tools for drug discovery, tomography technologies, and regulatory updates in the industry.
Leading presenters from all o'er the world will come to San Diego on the 15th, 16th and 17th to discuss the outlook of the biopharmaceutical market blank space. Presenting organizations include, Pfizer, Merck, Novartis, Eli Lilly, GSK, Aventis, Genentech, Amgen, Biogen Idec, NIH, FDA & many more.
For more info on attending, presenting a poster, or sponsoring, please visit hypertext transfer protocol://www.gtcbio.com.
About GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to help the substitution of biopharmaceutical and biomedical intelligence 'tween industry leadership, academic and government organizations, and the financial community.
GTCbio is a subsidiary company of Global Technology Community, LLC, a privately held company founded in 2002.
http://www.gtcbio.com
More information
Wednesday 6 August 2008
Veterans' Groups File Notice To Overturn Dismissal Of PTSD Care Suit
�
Two veterans groups on Monday filed a notice with the Ninth U.S. Circuit Court of Appeals in San Francisco to overturn the decision of a frown court judge that pink-slipped a stratum action suit seeking to force changes to the Department of Veterans Affairs' health caution system, the Washington Times reports (Hudson, Washington Times, 7/29). U.S. District Judge Samuel Conti in June dismissed the lawsuit, filed by the Veterans for Common Sense and the Veterans United for Truth. Lawyers for the deuce veterans groups said that staff shortages, long waits, inadequate guardianship and an adversarial appeals process for denied aid have created an "epidemic of suicides" among veterans. The case also said that VA was ignoring or delaying treatment of post-traumatic strain disorder for as many as 750,000 veterans. The cause did not seek redress but instead sought for the court to force VA to improve care for veterans, especially those with PTSD and other mental health issues.
In his ruling, Conti agreed with the veterans groups' claims that there was a high veteran suicide and PTSD rate; that the VA was short-handed; and that there were long wait periods for hearing veterans' appeals of benefit denials. In addition, Conti found that members of the two groups "have faced significant delays in receiving disability benefits and medical care from the VA," often with "dire consequences." However, he noted that a absolute majority of veterans have been seen inside 30 years. He added that although the delays were "significant," they did not violate a veteran's right to due sue because thither was no consensus on how "timely" processing would be defined (Kaiser Daily Health Policy Report, 6/26).
A statement from the veterans groups said that a "flood of veterans with mental health problems will proceed to increment" as soldiers continue to be sent to Iraq and Afghanistan for multiple tours of duty (Washington Times, 7/29).
Reprinted with kind permission from hTTP://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or polarity up for email delivery at hTTP://www.kaisernetwork.
Two veterans groups on Monday filed a notice with the Ninth U.S. Circuit Court of Appeals in San Francisco to overturn the decision of a frown court judge that pink-slipped a stratum action suit seeking to force changes to the Department of Veterans Affairs' health caution system, the Washington Times reports (Hudson, Washington Times, 7/29). U.S. District Judge Samuel Conti in June dismissed the lawsuit, filed by the Veterans for Common Sense and the Veterans United for Truth. Lawyers for the deuce veterans groups said that staff shortages, long waits, inadequate guardianship and an adversarial appeals process for denied aid have created an "epidemic of suicides" among veterans. The case also said that VA was ignoring or delaying treatment of post-traumatic strain disorder for as many as 750,000 veterans. The cause did not seek redress but instead sought for the court to force VA to improve care for veterans, especially those with PTSD and other mental health issues.
In his ruling, Conti agreed with the veterans groups' claims that there was a high veteran suicide and PTSD rate; that the VA was short-handed; and that there were long wait periods for hearing veterans' appeals of benefit denials. In addition, Conti found that members of the two groups "have faced significant delays in receiving disability benefits and medical care from the VA," often with "dire consequences." However, he noted that a absolute majority of veterans have been seen inside 30 years. He added that although the delays were "significant," they did not violate a veteran's right to due sue because thither was no consensus on how "timely" processing would be defined (Kaiser Daily Health Policy Report, 6/26).
A statement from the veterans groups said that a "flood of veterans with mental health problems will proceed to increment" as soldiers continue to be sent to Iraq and Afghanistan for multiple tours of duty (Washington Times, 7/29).
Reprinted with kind permission from hTTP://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or polarity up for email delivery at hTTP://www.kaisernetwork.
Subscribe to:
Posts (Atom)